CRISPR company Intellia names CFO
This article was originally published in Scrip
Executive Summary
Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 technology for gene editing and repair, has appointed Sapna Srivastava chief financial and strategy officer. Dr Srivastava has experience in the biopharmaceutical industry and on Wall Street. Prior to joining Intellia she was senior analyst and team leader of the biotechnology group at Goldman Sachs.